Latest publications

Exploring Social Health in Patients with Atopic Dermatitis: An Observational, Cross-sectional, Questionnaire Based Study on Social Participation and Emotional Support. Kamphuis E, Loman L, De Bruin-Weller M, Schuttelaar ML et al. Acta Derm Venereol 2025 Jan 08; 105:adv41129

The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials. Guttman-Yassky E, Rosmarin D, De Bruin-Weller M, Weidinger S, Bieber T, Hong HC et al. J Am Acad Dermatol 2024 Dec 27

Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Yosipovitch G, De Bruin-Weller M, Wiseman M, Elberling J, Gutermuth J, Pierce E et al. Clin Exp Dermatol 2024 Dec 16

Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels. Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W et al. Allergy 2024 Dec 14

Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients. Dekkers C, Smits H, Stölzl D, Spekhorst L, Knol E, Van Wijk F et al. Clin Exp Allergy 2025 Jan; 55(1):97-99

Assessing Disease Control in Patients with Atopic Dermatitis by Using the Atopic Dermatitis Control Tool in Daily Practice. Chen R, Loman L, Van der Gang LF, Sloot MM, De Bruin-Weller MS, Schuttelaar MLA et al. Dermatology 2024; 240(5-6):732-738

Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. Van der Rijst LP, Kamphuis E, Schuttelaar MLA, Hurmuz R, Seyger MMB, Caron AGM et al. JAMA Dermatol 2025 Jan 01; 161(1):12-21

Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. Paller AS, De Bruin-Weller M, Marcoux D, Baselga E, Oliveira de Carvalho V, Ardusso LRF et al. J Am Acad Dermatol 2025 Feb; 92(2):242-251

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, Mohammad Porras N et al. Allergy 2024 Oct 08

Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Simpson E, Fernández-Peñas P, De Bruin-Weller M, Lio PA, Chu CY, Ezzedine K et al. Adv Ther 2024 Sep 09

Reply to Sujoy Khan. Van der Rijst LP, De Winter-de Groot KM, De Bruin-Weller MS, De Graaf M et al. Pediatr Allergy Immunol 2024 Aug; 35(8):e14222

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. Boesjes CM, Kamphuis E, De Graaf M, Spekhorst LS, Haeck I, Van der Gang LF et al. JAMA Dermatol 2024 Oct 01; 160(10):1044-1055

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Blauvelt A, Eyerich K, Irvine AD, De Bruin-Weller M, Kwatra SG, Gooderham M et al. Dermatol Ther (Heidelb) 2024 Sep; 14(9):2621-2630

Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients. Van der Rijst LP, Hilbrands MS, Zuithoff NPA, De Bruin-Weller MS, Knulst AC, Le TM et al. Clin Transl Allergy 2024 Jul; 14(7):e12381

Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, Porras NM et al. JAMA Dermatol 2024 Sep 01; 160(9):927-935